14.45 | 11.45 Liquid Biopsy Assay Screening : A Payor’s Perspective
Time: 2:45 pm
day: Day Three
- The critical importance of assay sensitivity and specificity to act as a decision maker, not descriptive assets
- How can clinical utility of translational genomics be better demonstrated to payors?
- Kaiser Permanente assay approval process: what are payors looking for to cover assays within policy?
- Where are cell free tumor DNA assays most needed clinically?